GET DAILY SIGNALSInMed Pharmaceuticals (INM) Shares Advance +17% Amid Merger Progress
Key Takeaways
- INM shares climbed roughly 17% over the last 30 days, moving from about $13.30 to $15.56 as the company's merger with Mentari Therapeutics moved toward completion.
- The advance was driven primarily by the definitive merger with migraine-focused biotech Mentari, which closed on November 6, 2026.
- Shareholders approved the merger, a corporate name change, and a 1-for-10 reverse stock split at the company's annual meeting on November 4.
- Over the last quarter, the stock rose a more modest roughly 6% after trading as low as about $12.80 in mid-September.
- The combined company is expected to trade under the ticker symbol MTRI, with legacy InMed programs carried through contingent value rights (CVRs).
- Get more information on this ticker's Price Targets, Earnings, and Forecast on additional pages.
- Explore Trending AI Robots for AI-driven trading insights across thousands of tickers.
Company Background and Strategic Shift
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. Its legacy pipeline consists of three programs addressing diseases with high unmet medical need: INM-901 for Alzheimer's disease, INM-089 for ocular indications including dry age-related macular degeneration, and INM-755 for dermatological conditions. Investors have followed the stock closely because of the company's clinical-stage drug development efforts and, more recently, its strategic transformation through a definitive merger agreement with Mentari Therapeutics, a clinical-stage biotechnology company developing next-generation migraine prevention therapies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INM shares rose approximately 17%, advancing from a close of about $13.30 to $15.56. The move accelerated in late October and early November as key merger milestones were completed, including the effective date of the company's registration statement, the announcement of the CVR distribution record date, and ultimately shareholder approval and closing of the transaction.
The picture over the last quarter is more measured. From a close of roughly $14.70 in early August, the stock gained about 6% through the most recent session. That headline figure masks meaningful volatility: shares declined to approximately $12.80 in mid-September before recovering as merger progress became clearer and pre-closing financing milestones were announced.
Key Drivers Behind the Recent 30-Day Advance
The dominant catalyst behind the 30-day advance was the progression and completion of the merger with Mentari Therapeutics. The company's registration statement on Form S-4 was declared effective on October 1, 2026. On October 26, InMed set November 5 as the record date for the distribution of contingent value rights (CVRs) to shareholders of record, a step that reinforced the deal's momentum.
On November 4, shareholders approved the merger, the corporate name change to Mentari Therapeutics, the redomestication from British Columbia to Nevada, and a 1-for-10 reverse stock split. The merger closed on November 6, with pre-merger Mentari completing approximately $490 million in gross proceeds from private financings, including the conversion of $50 million of convertible notes plus accrued interest. Trading was volatile around the record date, with a decline followed by a recovery as investors weighed the CVR entitlement mechanics against the combined company's strengthened cash position, which is expected to fund operations into 2029.
Broader Trends Over the Last Quarter
The broader multi-month trend was shaped by the merger narrative first announced in May 2026. Over the quarter, the stock traded in a wide range as investors assessed deal progress, financing terms, and the legacy InMed programs' future. The September pullback to roughly $12.80 coincided with a Nasdaq notification regarding minimum shareholders' equity compliance, driven in part by transaction-related expenses and the wind-down of the BayMedica subsidiary. As the transaction milestones approached and the combined company's approximately $490 million financing came into focus, sentiment improved, lifting shares through late October and early November.
Factors to Monitor Going Forward
Looking ahead, the key factors for investors to monitor center on the combined company's transition and clinical progress. Following the merger close, shares are expected to trade under the Mentari Therapeutics name and ticker, with legacy InMed programs represented by contingent value rights. The combined company's lead programs, MT-001 (an anti-PACAP monoclonal antibody) and MT-002 (an anti-PACAP and anti-CGRP bispecific antibody), are advancing toward Phase 2a readouts, with the approximately $490 million financing expected to extend the cash runway into 2029. Investors should also watch CVR-related developments tied to the potential monetization of INM-901, INM-089, and INM-755, as well as Nasdaq listing compliance and broader biotechnology sector sentiment. These factors are informational and do not constitute investment advice. From what I see, reviewing patterns with Tickeron’s AI Real Time Patterns can add useful context to these developments.
AI Tools in My Research Process
In tracking merger-related moves like this one, I’ve turned to Tickeron’s AI Trading Bots for additional perspective. The platform offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in the curated section. These bots vary widely in strategy, timeframe, and performance metrics, giving traders a range of approaches to evaluate. It’s designed to help investors quickly identify AI-driven strategies that are currently gaining traction, rather than requiring them to sort through the full catalog manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INM in upward trend: 10-day moving average crossed above 50-day moving average on October 27, 2026
The 10-day moving average for INM crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on INM as a result. In 79 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
INM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where INM advanced for three days, in 150 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for INM moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 30 cases where INM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INM broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. INM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: INM's P/B Ratio (79.518) is slightly higher than the industry average of (7.254). P/E Ratio (-4.987) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.891) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement